FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955910316> ?p ?o ?g. }

• W2955910316 endingPage "789" @default.
• W2955910316 startingPage "780" @default.
• W2955910316 abstract "This systematic review and meta-analysis investigated the efficacy and safety of glecaprevir and pibrentasvir (G/P) for chronic hepatitis C virus (HCV) infection. Pubmed, Embase, Cochrane Library and Scopus were searched to identify relevant studies through August 2018. Data from eligible studies were pooled and sustained virological response rates at 12 weeks’ post-treatment (SVR12) were calculated. Thirteen studies with 3082 patients were included and the overall SVR12 rate was 97.8%. The SVR12 rates of subgroups were: G/P 300 mg/120 mg and 200 mg/120 mg: 97.9% and 98.3%; HCV genotype (GT)1, GT2, GT3 and GT4-6: 99.8%, 99.2%, 96.1% and 100%; G/P and G/P plus ribavirin (RBV): 97.9% and 98.2%; G/P (300 mg/120 mg) for 8 weeks, 12 weeks and 16 weeks: 98.8%, 98.5% and 95.6%; treatment-naïve and treatment-experienced patients: 96.7% and 98.3%; patients without and with compensated cirrhosis: 99.4% and 98.8%; patients without and with human immunodeficiency virus (HIV) co-infection: 97.8% and 99.4%; and patients without and with severe renal impairment (SRI): 97.8% and 99.4%. Virological failure and relapse and serious drug-related adverse events were rare. These results indicate that 8- or 12-week G/P treatment achieved high SVR12 rates in HCV GTs 1-6 patients without or with compensated cirrhosis, with good safety profiles, irrespective of dose, RBV use, treatment-experience, HIV co-infection and renal impairment. Due to the limited number of evaluated patients with GT3 infection, further studies are needed to define optimal treatment duration for GT3 cirrhosis patients and patients with prior treatment experience of direct-acting antivirals." @default.
• W2955910316 created "2019-07-12" @default.
• W2955910316 creator A5016038041 @default.
• W2955910316 creator A5020727273 @default.
• W2955910316 creator A5031315906 @default.
• W2955910316 creator A5038611998 @default.
• W2955910316 creator A5045771501 @default.
• W2955910316 creator A5046145690 @default.
• W2955910316 creator A5060199673 @default.
• W2955910316 creator A5080316854 @default.
• W2955910316 creator A5081744785 @default.
• W2955910316 date "2019-12-01" @default.
• W2955910316 modified "2023-10-16" @default.
• W2955910316 title "Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: A systematic review and meta-analysis" @default.
• W2955910316 cites W1545034860 @default.
• W2955910316 cites W1888988496 @default.
• W2955910316 cites W1972821220 @default.
• W2955910316 cites W1988704207 @default.
• W2955910316 cites W2017044005 @default.
• W2955910316 cites W2022555003 @default.
• W2955910316 cites W2025524023 @default.
• W2955910316 cites W2067182451 @default.
• W2955910316 cites W2070902941 @default.
• W2955910316 cites W2078251659 @default.
• W2955910316 cites W2098923148 @default.
• W2955910316 cites W2120733999 @default.
• W2955910316 cites W2125435699 @default.
• W2955910316 cites W2127685726 @default.
• W2955910316 cites W2133036275 @default.
• W2955910316 cites W2137354005 @default.
• W2955910316 cites W2150652264 @default.
• W2955910316 cites W2267325223 @default.
• W2955910316 cites W2296452901 @default.
• W2955910316 cites W2301258722 @default.
• W2955910316 cites W2487282667 @default.
• W2955910316 cites W2553101543 @default.
• W2955910316 cites W2564813289 @default.
• W2955910316 cites W2565117603 @default.
• W2955910316 cites W2605698336 @default.
• W2955910316 cites W2667085915 @default.
• W2955910316 cites W2746084941 @default.
• W2955910316 cites W2751450406 @default.
• W2955910316 cites W2754580087 @default.
• W2955910316 cites W2756296447 @default.
• W2955910316 cites W2756644889 @default.
• W2955910316 cites W2758719604 @default.
• W2955910316 cites W2759486647 @default.
• W2955910316 cites W2761085897 @default.
• W2955910316 cites W2766054212 @default.
• W2955910316 cites W2768486652 @default.
• W2955910316 cites W2784719900 @default.
• W2955910316 cites W2788216918 @default.
• W2955910316 cites W2791786965 @default.
• W2955910316 cites W2792995303 @default.
• W2955910316 cites W2793184892 @default.
• W2955910316 doi "https://doi.org/10.1016/j.ijantimicag.2019.07.005" @default.
• W2955910316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31284039" @default.
• W2955910316 hasPublicationYear "2019" @default.
• W2955910316 type Work @default.
• W2955910316 sameAs 2955910316 @default.
• W2955910316 citedByCount "18" @default.
• W2955910316 countsByYear W29559103162019 @default.
• W2955910316 countsByYear W29559103162020 @default.
• W2955910316 countsByYear W29559103162021 @default.
• W2955910316 countsByYear W29559103162022 @default.
• W2955910316 countsByYear W29559103162023 @default.
• W2955910316 crossrefType "journal-article" @default.
• W2955910316 hasAuthorship W2955910316A5016038041 @default.
• W2955910316 hasAuthorship W2955910316A5020727273 @default.
• W2955910316 hasAuthorship W2955910316A5031315906 @default.
• W2955910316 hasAuthorship W2955910316A5038611998 @default.
• W2955910316 hasAuthorship W2955910316A5045771501 @default.
• W2955910316 hasAuthorship W2955910316A5046145690 @default.
• W2955910316 hasAuthorship W2955910316A5060199673 @default.
• W2955910316 hasAuthorship W2955910316A5080316854 @default.
• W2955910316 hasAuthorship W2955910316A5081744785 @default.
• W2955910316 hasConcept C126322002 @default.
• W2955910316 hasConcept C197934379 @default.
• W2955910316 hasConcept C203014093 @default.
• W2955910316 hasConcept C2522874641 @default.
• W2955910316 hasConcept C2776408679 @default.
• W2955910316 hasConcept C2776455275 @default.
• W2955910316 hasConcept C2776478404 @default.
• W2955910316 hasConcept C2777214474 @default.
• W2955910316 hasConcept C2780040827 @default.
• W2955910316 hasConcept C71924100 @default.
• W2955910316 hasConcept C90924648 @default.
• W2955910316 hasConcept C95190672 @default.
• W2955910316 hasConceptScore W2955910316C126322002 @default.
• W2955910316 hasConceptScore W2955910316C197934379 @default.
• W2955910316 hasConceptScore W2955910316C203014093 @default.
• W2955910316 hasConceptScore W2955910316C2522874641 @default.
• W2955910316 hasConceptScore W2955910316C2776408679 @default.
• W2955910316 hasConceptScore W2955910316C2776455275 @default.
• W2955910316 hasConceptScore W2955910316C2776478404 @default.
• W2955910316 hasConceptScore W2955910316C2777214474 @default.
• W2955910316 hasConceptScore W2955910316C2780040827 @default.
• W2955910316 hasConceptScore W2955910316C71924100 @default.

• next